Promoted Interaction of Nuclear Factor-κB With Demethylated Purinergic P2X3 Receptor Gene Contributes to Neuropathic Pain in Rats With Diabetes

Diabetes. 2015 Dec;64(12):4272-84. doi: 10.2337/db15-0138. Epub 2015 Jun 30.

Abstract

Painful diabetic neuropathy is a common complication of diabetes produced by mechanisms that as yet are incompletely defined. The aim of this study was to investigate the roles of nuclear factor-κB (NF-κB) in the regulation of purinergic receptor P2X ligand-gated ion channel 3 (P2X3R) plasticity in dorsal root ganglion (DRG) neurons of rats with painful diabetes. Here, we showed that hindpaw pain hypersensitivity in streptozocin-induced diabetic rats was attenuated by treatment with purinergic receptor antagonist suramin or A-317491. The expression and function of P2X3Rs was markedly enhanced in hindpaw-innervated DRG neurons in diabetic rats. The CpG (cytosine guanine dinucleotide) island in the p2x3r gene promoter region was significantly demethylated, and the expression of DNA methyltransferase 3b was remarkably downregulated in DRGs in diabetic rats. The binding ability of p65 (an active form of NF-κB) with the p2x3r gene promoter region and p65 expression were enhanced significantly in diabetes. The inhibition of p65 signaling using the NF-κB inhibitor pyrrolidine dithiocarbamate or recombinant lentiviral vectors designated as lentiviral vector-p65 small interfering RNA remarkably suppressed P2X3R activities and attenuated diabetic pain hypersensitivity. Insulin treatment significantly attenuated pain hypersensitivity and suppressed the expression of p65 and P2X3Rs. Our findings suggest that the p2x3r gene promoter DNA demethylation and enhanced interaction with p65 contributes to P2X3R sensitization and diabetic pain hypersensitivity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CpG Islands / drug effects
  • DNA (Cytosine-5-)-Methyltransferases / antagonists & inhibitors
  • DNA (Cytosine-5-)-Methyltransferases / genetics
  • DNA (Cytosine-5-)-Methyltransferases / metabolism
  • DNA Methylation / drug effects
  • DNA Methyltransferase 3B
  • Diabetes Mellitus, Experimental / complications*
  • Diabetes Mellitus, Experimental / drug therapy
  • Diabetic Neuropathies / enzymology
  • Diabetic Neuropathies / metabolism*
  • Diabetic Neuropathies / prevention & control
  • Epigenesis, Genetic* / drug effects
  • Female
  • Ganglia, Spinal / drug effects
  • Ganglia, Spinal / enzymology
  • Ganglia, Spinal / metabolism*
  • Gene Expression Regulation / drug effects
  • Hindlimb
  • Hypoglycemic Agents / therapeutic use
  • Insulin / therapeutic use
  • Nerve Tissue Proteins / antagonists & inhibitors
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / metabolism
  • Neuralgia / complications
  • Neuralgia / metabolism*
  • Neuralgia / prevention & control
  • Neurons / drug effects
  • Neurons / enzymology
  • Neurons / metabolism
  • Promoter Regions, Genetic / drug effects
  • Purinergic P2X Receptor Antagonists / therapeutic use
  • RNA Interference
  • Rats, Sprague-Dawley
  • Receptors, Purinergic P2X3 / chemistry
  • Receptors, Purinergic P2X3 / genetics
  • Receptors, Purinergic P2X3 / metabolism*
  • Transcription Factor RelA / agonists
  • Transcription Factor RelA / antagonists & inhibitors
  • Transcription Factor RelA / genetics
  • Transcription Factor RelA / metabolism*

Substances

  • Hypoglycemic Agents
  • Insulin
  • Nerve Tissue Proteins
  • P2rx3 protein, rat
  • Purinergic P2X Receptor Antagonists
  • Receptors, Purinergic P2X3
  • Rela protein, rat
  • Transcription Factor RelA
  • DNA (Cytosine-5-)-Methyltransferases